H-(Pro)2-OH*TFA salt | 91474-69-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-(Pro)2-OH*TFA salt
• 英文别名: L-Pro-L-Pro(OH)*TFA；(2S)-1-[(2S)-pyrrolidin-1-ium-2-carbonyl]pyrrolidine-2-carboxylic acid;2,2,2-trifluoroacetate
• CAS: 91474-69-0
• 化学式: C₂HF₃O₂*C₁₀H₁₆N₂O₃
• 分子量: 326.273
• InChiKey: LXGPMKJEKMOQOB-WSZWBAFRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.91
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  Fmoc-L-脯氨酸 、 三氟乙酸 在 N,N-二异丙基乙胺 、 哌啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 以18 mg的产率得到H-(Pro)2-OH*TFA salt
  参考文献：
  名称：

  通过磷脂双层渗透，皮肤细胞渗透，血浆稳定性以及α-和β-寡脯氨酸衍生物的CD光谱。

  摘要：

  在对氨基酸脯氨酸在生命化学中所起的特殊作用进行了调查之后，讨论了含聚阳离子脯氨酸的肽的细胞穿透特性，以及Giralt小组（J.Am. Soc。2002，124，8876），据此，荧光素标记的十四碳脯氨酸被大鼠肾细胞（NRK-49F）缓慢吸收。在这里，我们描述了我们先前提到的（Chem。Biodiversity 2004，1，1111）六-β（3）-Pro衍生物穿透成纤维细胞的观察结果的细节，并且我们提出了对寡聚L-和oligo-D-α-脯氨酸，以及不带有和带有荧光标记的oligo-β（2）h-和oligo-β（3）h-脯氨酸（1-8;图1）。用nanoFAST生物芯片技术检测到无蛋白质磷脂双层的渗透（图2-4）。首次将这种方法用于定量测定跨脂质双层的细胞穿透肽（CPP）的转运速率。用小鼠（3T3）和人包皮成纤维细胞（HFF；图5和6-8，分别）观察到细胞渗透。肝素稳定的人血浆中寡脯氨酸的稳

  DOI：

  10.1002/cbdv.201200393
• 作为试剂：
  描述：

  环己酮 、 异丁醛 在 alumina 、 H-(Pro)2-OH*TFA salt 作用下， 以 二甲基亚砜 为溶剂， 反应 44.0h， 以35%的产率得到
  参考文献：
  名称：

  Reversal of Enantioselectivity in Aldol Reaction: New Data on Proline/γ-Alumina Organic–Inorganic Hybrid Catalysts

  摘要：

  We report new results on the aldol reactions between aldehydes of three different types (aromatic, aliphatic and cycloaliphatic) and acetone/cycloalkanones as reaction partners, driven by organic-inorganic hybrid catalyst Pro/gamma-Al2O3. In contrast to the homogeneous liquid-phase reaction, over Pro/gamma-Al2O3 reversal of the enantioselection in up to 20-40 % ee depending on the structure of the aldehyde was observed in reactions of acetone. Reversal of the ee in the presence of gamma-Al2O3 cannot be generalized, as it has only been observed for acetone among the ketones studied by us. It was proven using methods of a great variety such as ultrasonic irradiation, reuse measurements on used catalyst and the filtrate of the first reaction, measurements on the l-Pro-l-Pro(OH) dipeptide, studies using mixtures of l-Pro and d-Pro that the organic-inorganic hybrid catalyst Pro/gamma-Al2O3 formed in situ is responsible for reversal of the ee. In the reactions of cycloalkanones there is presumably competition between the liquid-phase and the surface reaction over Pro/gamma-Al2O3 with preference for the former. Based on these results a surface reaction pathway was proposed. Although, the ees obtained under heterogeneous catalytic conditions are low, further studies may lead to application of this unusual phenomenon for obtaining chiral heterogeneous catalysts suitable for the preparation of the desired enantiomer of a chiral compound using the same chiral source.

  DOI：

  10.1007/s10562-013-1177-1

文献信息

• NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3848054A1

  公开（公告）日：2021-07-14

  Desired is development of novel CDN derivatives having STING agonist activity; and a therapeutic agents and/or therapeutic methods using the novel CDN derivatives for diseases associated with STING agonist activity. Further desired is development of a therapeutic agents and/or therapeutic methods capable of delivering the novel CDN derivatives specifically to targeted cells and organs for diseases associated with STING agonist activity. The present invention provides novel CDN derivatives having potent STING agonist activity, and antibody-CDN derivative conjugates including the novel CDN derivatives.

  希望开发出具有 STING 激动剂活性的新型 CDN 衍生物；以及使用新型 CDN 衍生物治疗与 STING 激动剂活性相关疾病的治疗剂和/或治疗方法。还希望开发一种治疗剂和/或治疗方法，能够将新型 CDN 衍生物特异性地输送到靶细胞和器官，以治疗与 STING 激动剂活性相关的疾病。本发明提供了具有强效 STING 激动剂活性的新型 CDN 衍生物，以及包括新型 CDN 衍生物的抗体-CDN 衍生物共轭物。